Long-term trial of an alpha adrenoceptor blocking drug (Indoramin) in asthma. A preliminary report.
Eight patients suffering from both asthma and migraine underwent a clinical trial for 3 months of indoramin, an alpha adrenoceptor antagonist with antihistamine and antiserotonin activity. Patients were told indoramin was prescribed for migraine prophylaxis. In three asthmatic patients there was a marked increase in airflow meter (AFM) readings which were recorded daily, the remaining five showing no significant change or a decrease in AFM readings. Indoramin did not appear to potentiate the action of the beta sympathomimetic aerosols. It is suggested that a small population of asthmatic patients may derive therapeutic benefit from an alpha adrenoceptor antagonist. Seven of the eight patients experienced a 50% decrease in the frequency of their migraine headaches.
D000293:Adolescent; D000328:Adult; D001249:Asthma / Q000150:complications / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000627:therapeutic use; D002940:Circadian Rhythm; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004357:Drug Synergism; D005260:Female; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D007217:Indoramin / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000150:complications / Q000517:prevention & control*; D012123:Pulmonary Ventilation / Q000187:drug effects
D001993:Bronchodilator Agents; D007211:Indoles; D007217:Indoramin